Rapport Therapeutics
Recent Finacing
Series B
Recent Raise
$150M
Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.
Focus Areas
Biotechnology
Neurological Disorders
Clinical-stage Therapeutics
Investors